Eureka Therapeutics

Eureka Therapeutics is an antibody drug developer dedicated to improving the safety of T-cell therapies and developing T-cell therapies for malignant hematological diseases and solid tumors. Eureka Therapeutics' core technology revolves around its proprietary ARTEMIS T-cell receptor platform and E-ALPHA phage display library, discovering and designing human antibodies targeting intracellular targets through MHC Class I complexes. The company is developing novel cancer therapeutics targeting intracellular oncogenes and cell surface antigens.